How Management Consulting Firms Improve Value Access

Getting a new therapy approved is only half the battle. The harder, less visible fight is making sure patients can actually get it, and that payers agree to cover it at a price that makes the whole enterprise worthwhile. That fight has quietly become one of the more lucrative corners of healthcare advisory work.

The Gap Between Approval and Adoption

A drug or device clearing regulatory review doesn't guarantee it reaches patients. Insurers, national health systems, and hospital formularies each apply their own criteria before a product gets reimbursed or stocked, and those criteria rarely align neatly with what regulators required for approval.

This gap is where a lot of avoidable value gets lost. A manufacturer can spend a decade and billions of dollars developing something genuinely useful, only to see uptake stall because nobody built the evidence package payers actually wanted, or because the pricing strategy didn't account for how a particular country's health system evaluates cost-effectiveness.

Why Outside Expertise Gets Called In

This is specialized enough, and different enough market to market, that most manufacturers don't try to handle it entirely in-house. Management consulting firms with dedicated healthcare and life sciences practices have built entire service lines around exactly this problem, mapping out reimbursement pathways, building the health economics models payers expect, and running the negotiations that determine what a product will actually be worth once it's on the market.

The work isn't glamorous. It's closer to translation than strategy: taking clinical trial data and reshaping it into the specific format a given payer's review committee requires, then doing it again for the next country with entirely different requirements.

Not all management consulting firms compete in this niche the same way. Some built their practice through decades of pharmaceutical client relationships and treat this work as one service among many within a broader life sciences practice. Others have spun up specialized boutiques that do nothing else, betting that deep focus outperforms breadth when the subject matter is this technical.

The Global Complication

None of this work translates cleanly across borders. A pricing and evidence strategy that succeeds with a US payer can fail outright in a country with government-run price negotiation, where the criteria for approval are shaped as much by political budget constraints as by clinical data. Manufacturers launching in a dozen markets simultaneously are effectively running a dozen different negotiations, each with its own evidence requirements, timelines, and cultural expectations about how aggressively a company can push back on an initial pricing offer.

That complexity is part of why manufacturers rarely build this capability entirely in-house, even large ones with substantial teams of their own. Keeping pace with regulatory and reimbursement changes across dozens of jurisdictions requires a breadth of local knowledge that's expensive to maintain permanently, but is exactly what outside specialists are built to provide on an as-needed basis.

Value Access as Its Own Discipline

What used to be a late-stage add-on to a launch plan is increasingly treated as its own discipline, one that starts well before a product reaches approval. Getting value access strategy right early means designing trials with payer requirements in mind from the start, rather than trying to retrofit evidence after the fact.

Companies that build this thinking in early tend to launch faster in more markets and negotiate from a stronger position. Those that treat it as an afterthought often find themselves re-running studies or accepting worse pricing terms simply because they can't produce the evidence a payer wants in the timeframe available.

What Separates the Firms That Do This Well

Not every advisory firm is equally good at this work, and the ones that stand out tend to combine three things: genuine clinical and regulatory fluency, deep familiarity with how individual payer systems actually make decisions, and enough negotiating experience to know where there's real room to move on price versus where a payer's position is fixed.

That combination is harder to build than it sounds, which is part of why this remains a specialized niche rather than a service every generalist firm offers well. Manufacturers picking a partner for this work are, in effect, picking a team that will shape how much of their product's real-world value they actually capture, and that's not a decision most companies take lightly, or should.

Reputation in this niche tends to travel through referrals rather than marketing, since the buyers making these decisions are a relatively small, tightly networked group of market access executives who compare notes on which firms actually delivered versus which ones just produced a polished deck. That dynamic rewards firms with a track record of measurable outcomes, faster approvals, better negotiated prices, fewer resubmissions, over firms that are simply well known.

Powered by Froala Editor